Spring Bank Pharmaceuticals (SBPH) Stock Price, News & Analysis

Company Overview

Spring Bank Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for the treatment of a range of cancers and inflammatory diseases using its proprietary small molecule nucleotide platform. The company is developing SB 11285, a next-generation immunotherapeutic cyclic dinucleotide for the treatment of selected cancers; novel STING antagonist compounds for the treatment of autoimmune and inflammatory diseases; and novel platform to enable the targeted delivery of payload molecules. It has a collaboration agreement with with Roche to explore the co-administration of SB 11285. The company was formerly known as Spring Bank Technologies, Inc. and changed its name to Spring Bank Pharmaceuticals, Inc. in May 2008. Spring Bank Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Hopkinton, Massachusetts.

Key Stats

• Today's Range: N/A
• 50-Day Range: $1.21 to $10.39
• 52-Week Range: N/A
• Volume: N/A
• Average Volume: 177,606 shs
• Market Capitalization: $122.94 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

SBPH Stock Analysis - Frequently Asked Questions

How were Spring Bank Pharmaceuticals' earnings last quarter?

Spring Bank Pharmaceuticals, Inc. (NASDAQ:SBPH) released its quarterly earnings results on Sunday, November, 8th. The company reported ($0.31) EPS for the quarter, missing analysts' consensus estimates of ($0.25) by $0.06.

When did Spring Bank Pharmaceuticals IPO?

Spring Bank Pharmaceuticals (SBPH) raised $14 million in an IPO on Friday, May 6th 2016. The company issued 1,100,000 shares at a price of $12.00-$14.00 per share. Dawson James Securities acted as the underwriter for the IPO.

What other stocks do shareholders of Spring Bank Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Spring Bank Pharmaceuticals investors own include Intelsat (I), AMC Entertainment (AMC), Bank of America (BAC), Fossil Group (FOSL), Associated British Foods (ABF), Apollo Global Management (APO) and Chaarat Gold (CGH).

Company Calendar

• Last Earnings: 11/08/2020
• Today: 9/01/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical Preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:SBPH
• CIK: 1566373
• Web: www.springbankpharm.com
• Phone: 508-473-5993
• Fax: N/A
• Employees: 30
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($1.47)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$24.10 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -89.89%
• Return on Assets: -52.89%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.11
• Quick Ratio: 5.11

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.16 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 17,267,000
• Free Float: N/A
• Market Cap: $122.94 million
• Optionable: Not Optionable
• Beta: 1.07